Physician profile
Vikram Malik
NPI 1205356326
$12,448.86
in general payments reported to CMS, 2019-2025
37 companies · $2,755 in 2025
The $2,755 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $90.84 · 2021: $1,583 · 2022: $1,575 · 2023: $3,072 · 2024: $3,373 · 2025: $2,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,171 · Education: $29.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,171.27 |
| Education | $29.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,356.78 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,017.34 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,646.79 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,028.03 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $831.69 | 2021-2025 | Orladeyo |
| Csl Behring | $597.64 | 2021-2025 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $559.56 | 2023-2025 | |
| Pharming Healthcare, INC. | $342.10 | 2021-2025 | Ruconest |
| Optinose US, INC. | $281.12 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.44 | 2020-2025 | Takhzyro, Hyqvia, Cuvitru |
| Amgen INC. | $231.65 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $227.43 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Kaleo, INC. | $203.83 | 2022-2024 | Auvi-Q |
| Horizon Therapeutics Plc | $197.18 | 2020-2022 | |
| Alk-Abello, INC | $192.17 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikram Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.